EX-99.1 2 ef20058429_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, November 6, 2025 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. “We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025," stated Diem Nguyen, Chief Executive Officer. " As we look forward to the remainder of 2025 and prepare for 2026, we are focused on building upon our long track record as a successful partner with the U.S. Government and international governments to secure new procurement contracts and orders that will serve as the foundation of our revenues for the years to come.” Summary Financial Results ($ in millions, except Three Months Nine Months per share amounts) Ended September 30 …
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
SIGA Technologies Inc.
SIGANASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025.…
Company context
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.